CA2115270A1 - Utilisation du monomere de peptidoglycanne (pgm), de ses derives n-acyles et de ses complexes metalliques dans la preparation de medicaments pour la correction des etats d'immunosuppression et d'hepatosuppression - Google Patents
Utilisation du monomere de peptidoglycanne (pgm), de ses derives n-acyles et de ses complexes metalliques dans la preparation de medicaments pour la correction des etats d'immunosuppression et d'hepatosuppressionInfo
- Publication number
- CA2115270A1 CA2115270A1 CA002115270A CA2115270A CA2115270A1 CA 2115270 A1 CA2115270 A1 CA 2115270A1 CA 002115270 A CA002115270 A CA 002115270A CA 2115270 A CA2115270 A CA 2115270A CA 2115270 A1 CA2115270 A1 CA 2115270A1
- Authority
- CA
- Canada
- Prior art keywords
- pgm
- states
- immunosuppressive
- hepatosuppressive
- organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001506 immunosuppresive effect Effects 0.000 title claims abstract description 20
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 17
- 239000002184 metal Substances 0.000 title claims abstract description 17
- 238000012937 correction Methods 0.000 title claims abstract description 11
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 108010013639 Peptidoglycan Proteins 0.000 title claims abstract description 7
- 239000000178 monomer Substances 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 229940124326 anaesthetic agent Drugs 0.000 claims abstract description 7
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 7
- 238000001356 surgical procedure Methods 0.000 claims abstract description 4
- 206010002091 Anaesthesia Diseases 0.000 claims description 16
- 230000037005 anaesthesia Effects 0.000 claims description 16
- 238000001949 anaesthesia Methods 0.000 claims description 15
- 206010062016 Immunosuppression Diseases 0.000 claims description 14
- 206010040047 Sepsis Diseases 0.000 claims description 12
- 150000002739 metals Chemical class 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 15
- 229960003132 halothane Drugs 0.000 description 15
- 208000014674 injury Diseases 0.000 description 11
- 230000035939 shock Effects 0.000 description 11
- 230000008733 trauma Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002350 laparotomy Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000010513 Stupor Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008775 paternal effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000013296 A/J mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100279860 Caenorhabditis elegans epg-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001387976 Pera Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 101150098024 ple4 gene Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| YUP-1412/91 | 1991-08-15 | ||
| YU141291 | 1991-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2115270A1 true CA2115270A1 (fr) | 1993-03-04 |
Family
ID=25554075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002115270A Abandoned CA2115270A1 (fr) | 1991-08-15 | 1992-08-13 | Utilisation du monomere de peptidoglycanne (pgm), de ses derives n-acyles et de ses complexes metalliques dans la preparation de medicaments pour la correction des etats d'immunosuppression et d'hepatosuppression |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0600974A1 (fr) |
| JP (1) | JPH08506796A (fr) |
| BG (1) | BG98628A (fr) |
| CA (1) | CA2115270A1 (fr) |
| CZ (1) | CZ30194A3 (fr) |
| HR (1) | HRP920488A2 (fr) |
| HU (1) | HU9400420D0 (fr) |
| RU (1) | RU94027699A (fr) |
| SK (1) | SK17994A3 (fr) |
| WO (1) | WO1993003746A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI8611982A8 (en) * | 1986-11-19 | 1995-04-30 | Pliva Pharm & Chem Works | Process for preparing complexes of N-acethyl-glucosisaminyl-N-acethyl- muramoil-L-alanyl-D-izoglutaminyl-(L)-mezodiaminopimelyl-(D-amid)- (L)-alanyl-D-alanine |
| US4868155A (en) * | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts |
| YU62689A (en) * | 1989-03-27 | 1991-02-28 | Pliva Pharm & Chem Works | N-acyl derivatives of peptidoglican monomer, their pharmaceutically acceptable salts, process for preparing thereof and their use as immunity modulators and immunoadjuvant |
-
1992
- 1992-08-13 CA CA002115270A patent/CA2115270A1/fr not_active Abandoned
- 1992-08-13 EP EP92917699A patent/EP0600974A1/fr not_active Withdrawn
- 1992-08-13 WO PCT/EP1992/001859 patent/WO1993003746A1/fr not_active Application Discontinuation
- 1992-08-13 HU HU9400420A patent/HU9400420D0/hu unknown
- 1992-08-13 RU RU94027699/14A patent/RU94027699A/ru unknown
- 1992-08-13 SK SK179-94A patent/SK17994A3/sk unknown
- 1992-08-13 CZ CS94301A patent/CZ30194A3/cs unknown
- 1992-08-13 JP JP5504098A patent/JPH08506796A/ja active Pending
- 1992-09-25 HR HR920488A patent/HRP920488A2/hr not_active Application Discontinuation
-
1994
- 1994-03-01 BG BG98628A patent/BG98628A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9400420D0 (en) | 1994-08-29 |
| JPH08506796A (ja) | 1996-07-23 |
| RU94027699A (ru) | 1996-04-10 |
| SK17994A3 (en) | 1994-08-10 |
| CZ30194A3 (en) | 1994-06-15 |
| EP0600974A1 (fr) | 1994-06-15 |
| HRP920488A2 (en) | 1994-08-31 |
| BG98628A (en) | 1995-06-30 |
| WO1993003746A1 (fr) | 1993-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101511823B (zh) | 多功能生物活性化合物 | |
| KR100643553B1 (ko) | 백혈구 수를 증진시키기 위한 약제학적 조성물 | |
| US7381735B2 (en) | Ultrashort-acting opioids for transdermal application | |
| JPH0747543B2 (ja) | アシアロ糖蛋白抱合薬剤 | |
| DE69533399T2 (de) | Zyklische hexapeptid somatostatin analoga | |
| JPH09501413A (ja) | 滞留肺分泌物の治療方法 | |
| AU669155B2 (en) | Use of muramyl peptide for the treatment of toxicity | |
| KR880011199A (ko) | 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물 | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| JP4667870B2 (ja) | 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物 | |
| EA008621B1 (ru) | 4-тетразолил-4-фенилпиперидин производные для лечения боли | |
| GB1604850A (en) | Biologically active peptides | |
| PT89036B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo derivados de ergolina | |
| CN1324364A (zh) | 磷糖脂及其使用方法 | |
| WO2001024791A1 (fr) | Utilisation de combinaisons synergiques d'un antagoniste du recepteur de nk1 et d'un analogue de gaba dans des troubles mentaux | |
| CA2115270A1 (fr) | Utilisation du monomere de peptidoglycanne (pgm), de ses derives n-acyles et de ses complexes metalliques dans la preparation de medicaments pour la correction des etats d'immunosuppression et d'hepatosuppression | |
| JP5553306B2 (ja) | 放射線障害防護剤 | |
| JPH01311093A (ja) | 置換ｎ―グリコシルアミド類 | |
| US20110117211A1 (en) | Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Disease of Mucosa | |
| ES2371635T3 (es) | Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes. | |
| WO1996032958A1 (fr) | Technique de traitement de la douleur | |
| EP0000559A1 (fr) | Pentapeptide-N-alkoylamides et leurs sels, procédé de préparation de ces produits et leurs compositions pharmacologiques | |
| JPS63503542A (ja) | 新規組成物 | |
| JP4073986B2 (ja) | 脊髄潅流液 | |
| ES2350039T3 (es) | Compuestos inmunomoduladores que contienen gamma-glutamilo y beta-aspartilo y métodos con ellos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |